{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:03:56Z","timestamp":1791846236396,"version":"4.3.4"},"reference-count":263,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA279363"],"award-info":[{"award-number":["T32CA279363"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021533","name":"Morrison Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021533","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK137183"],"award-info":[{"award-number":["R01DK137183"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA248019"],"award-info":[{"award-number":["R01CA248019"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA266256"],"award-info":[{"award-number":["R01CA266256"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015927","name":"Evans Medical Foundation","doi-asserted-by":"publisher","award":["EPEF\u2010DRG2020"],"award-info":[{"award-number":["EPEF\u2010DRG2020"]}],"id":[{"id":"10.13039\/100015927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["EDS\u201026\u20101541279\u201001\u2010EDS ACC 3rd\u2010Su25"],"award-info":[{"award-number":["EDS\u201026\u20101541279\u201001\u2010EDS ACC 3rd\u2010Su25"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of select hematologic malignancies, where disease accessibility, well\u2010defined lineage antigens, and clinically manageable target cell depletion have enabled more durable responses. However, translation to solid tumors has been far more limited due to the structural, metabolic, and immunologic barriers that are less prominent in many blood cancers. This review uses hematologic malignancies as the standard for CAR T cell therapy success while synthesizing mechanistic insights from preclinical models and emerging data from early\u2010phase solid tumor trials. We define how antigen heterogeneity, impaired trafficking, metabolic suppression, immunosuppressive signaling, and on\u2010target, off\u2010tumor toxicity limit CAR T cell infiltration, persistence, and function in solid tumors. We also highlight recurring clinical patterns indicating that antitumor activity is most achievable when tumor\u2010enriched antigens are targeted, delivery strategies overcome physical barriers, and CAR T cells are engineered to resist exhaustion and suppression within hostile microenvironments. By evaluating next\u2010generation approaches, including cytokine armoring, multi\u2010antigen and logic\u2010gated recognition, regional delivery, and regulatable safety circuits, we propose a model for rational CAR T cell design tailored to solid tumor biology while informed by the principles underlying hematologic success. These insights support context\u2010dependent engineered immunotherapies capable of extending the durability and safety achieved in blood cancers to solid malignancies.<\/jats:p>","DOI":"10.1002\/hon.70209","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:46:37Z","timestamp":1781523997000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CAR T Cell Therapy in Solid Tumors: Lessons From Early\u2010Phase Clinical Trials and Biological Barriers to Efficacy"],"prefix":"10.1002","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5367-5322","authenticated-orcid":false,"given":"Kasie","family":"Liu","sequence":"first","affiliation":[{"name":"MD Anderson Mays Cancer Center at UT Health San Antonio  San Antonio Texas USA"},{"name":"Department of Cell Systems and Anatomy UT Health San Antonio  San Antonio Texas USA"},{"name":"Department of Biology Trinity University  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Truong","family":"Pham","sequence":"additional","affiliation":[{"name":"MD Anderson Mays Cancer Center at UT Health San Antonio  San Antonio Texas USA"},{"name":"Department of Cell Systems and Anatomy UT Health San Antonio  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaozi","family":"Fu","sequence":"additional","affiliation":[{"name":"MD Anderson Mays Cancer Center at UT Health San Antonio  San Antonio Texas USA"},{"name":"Department of Cell Systems and Anatomy UT Health San Antonio  San Antonio Texas USA"},{"name":"Department of Thoracic Surgery The First Affiliated Hospital of Zhejiang University School of Medicine  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LuZhe","family":"Sun","sequence":"additional","affiliation":[{"name":"MD Anderson Mays Cancer Center at UT Health San Antonio  San Antonio Texas USA"},{"name":"Department of Cell Systems and Anatomy UT Health San Antonio  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Huang","sequence":"additional","affiliation":[{"name":"MD Anderson Mays Cancer Center at UT Health San Antonio  San Antonio Texas USA"},{"name":"Department of Cell Systems and Anatomy UT Health San Antonio  San Antonio Texas USA"},{"name":"Department of Pathology and Laboratory Medicine UT Health San Antonio  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"e_1_2_16_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201002\u2010769208"},{"key":"e_1_2_16_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709919"},{"key":"e_1_2_16_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010020\u20100760\u2010x"},{"key":"e_1_2_16_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709866"},{"key":"e_1_2_16_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1804980"},{"key":"e_1_2_16_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1914347"},{"key":"e_1_2_16_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"e_1_2_16_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720"},{"key":"e_1_2_16_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01217"},{"key":"e_1_2_16_11_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1716266115"},{"key":"e_1_2_16_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0b013e318194a6e8"},{"key":"e_1_2_16_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010018\u20100010\u20101"},{"key":"e_1_2_16_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007057"},{"key":"e_1_2_16_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2019.10.005"},{"key":"e_1_2_16_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1024362"},{"key":"e_1_2_16_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1708566"},{"key":"e_1_2_16_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01956"},{"key":"e_1_2_16_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010018\u20100201\u20109"},{"key":"e_1_2_16_20_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.162.1.352"},{"key":"e_1_2_16_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.sj.6300134"},{"key":"e_1_2_16_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0b013e3181ac6138"},{"key":"e_1_2_16_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1103849"},{"key":"e_1_2_16_24_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002842"},{"key":"e_1_2_16_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092\u20108674(91)90314\u2010o"},{"key":"e_1_2_16_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838"},{"key":"e_1_2_16_27_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci46110"},{"key":"e_1_2_16_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051182"},{"key":"e_1_2_16_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478"},{"key":"e_1_2_16_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1074\u20107613(00)80025\u20104"},{"key":"e_1_2_16_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12471"},{"key":"e_1_2_16_32_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.25.13897"},{"key":"e_1_2_16_33_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3010162"},{"key":"e_1_2_16_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.cd\u201021\u20100407"},{"key":"e_1_2_16_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.01.020"},{"key":"e_1_2_16_36_1","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aap9777"},{"key":"e_1_2_16_37_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg6986"},{"key":"e_1_2_16_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.cd\u201020\u20101661"},{"key":"e_1_2_16_39_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci33522"},{"key":"e_1_2_16_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018\u2010025\u201001009\u2010x"},{"key":"e_1_2_16_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/329506a0"},{"key":"e_1_2_16_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/344742a0"},{"key":"e_1_2_16_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010017\u201001062\u2010w"},{"key":"e_1_2_16_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm827"},{"key":"e_1_2_16_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201007\u20100674"},{"key":"e_1_2_16_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.08.036"},{"key":"e_1_2_16_47_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402346"},{"key":"e_1_2_16_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.06.008"},{"key":"e_1_2_16_49_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158013"},{"key":"e_1_2_16_50_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.12.2205"},{"key":"e_1_2_16_51_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006034"},{"key":"e_1_2_16_52_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe7378"},{"key":"e_1_2_16_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.01.008"},{"key":"e_1_2_16_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.can\u201008\u20102281"},{"key":"e_1_2_16_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201015\u20102463"},{"key":"e_1_2_16_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326\u20106066.CIR\u201016\u20100188"},{"key":"e_1_2_16_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0002\u20109440(10)65424\u20107"},{"key":"e_1_2_16_58_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.can\u201006\u20100261"},{"key":"e_1_2_16_59_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007974"},{"key":"e_1_2_16_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0b013e3181ee6675"},{"key":"e_1_2_16_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1395997"},{"key":"e_1_2_16_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1047"},{"key":"e_1_2_16_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2004.04.006"},{"issue":"3","key":"e_1_2_16_64_1","first-page":"322","article-title":"Expression of Adhesion Molecules on the Endothelium of Normal Tissue Vessels and Vascular Tumors","volume":"69","author":"Kuzu I.","year":"1993","journal-title":"Laboratory Investigation"},{"key":"e_1_2_16_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/12.5.671"},{"key":"e_1_2_16_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/12.5.671"},{"key":"e_1_2_16_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v88.2.667.bloodjournal882667"},{"key":"e_1_2_16_68_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.2001.281.5.g1309"},{"key":"e_1_2_16_69_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13073\u2010022\u201001110\u20101"},{"key":"e_1_2_16_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010024\u201001068\u2010w"},{"key":"e_1_2_16_71_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.05\u20104493com"},{"key":"e_1_2_16_72_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111687"},{"key":"e_1_2_16_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605238"},{"key":"e_1_2_16_74_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741\u20107015\u20106\u201011"},{"key":"e_1_2_16_75_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci45817"},{"key":"e_1_2_16_76_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1320318110"},{"key":"e_1_2_16_77_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.CD\u201019\u20100094"},{"key":"e_1_2_16_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3833"},{"key":"e_1_2_16_79_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1809"},{"key":"e_1_2_16_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0996\u2010992"},{"key":"e_1_2_16_81_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/898165"},{"key":"e_1_2_16_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010023\u201001908\u2010x"},{"key":"e_1_2_16_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature06868"},{"key":"e_1_2_16_84_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215397109"},{"key":"e_1_2_16_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature22367"},{"key":"e_1_2_16_86_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131916"},{"key":"e_1_2_16_87_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.CAN\u201013\u20101506"},{"key":"e_1_2_16_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2006.10.016"},{"key":"e_1_2_16_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2714"},{"key":"e_1_2_16_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.04.001"},{"key":"e_1_2_16_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102006\u201007\u2010035972"},{"key":"e_1_2_16_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.08.011"},{"key":"e_1_2_16_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200838289"},{"key":"e_1_2_16_94_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.7.4476"},{"key":"e_1_2_16_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016"},{"key":"e_1_2_16_96_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.can\u201004\u20100465"},{"key":"e_1_2_16_97_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.9.1363"},{"key":"e_1_2_16_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102013\u201001\u2010480129"},{"key":"e_1_2_16_99_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.025924"},{"key":"e_1_2_16_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018\u2010021\u201003818\u20106"},{"key":"e_1_2_16_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.12.030"},{"key":"e_1_2_16_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.04.023"},{"key":"e_1_2_16_103_1","doi-asserted-by":"publisher","DOI":"10.1038\/s44319\u2010024\u201000365\u20106"},{"key":"e_1_2_16_104_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1002202"},{"key":"e_1_2_16_105_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13490"},{"key":"e_1_2_16_106_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0914433107"},{"key":"e_1_2_16_107_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102022\u2010006287"},{"key":"e_1_2_16_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.05.035"},{"key":"e_1_2_16_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.10.020"},{"key":"e_1_2_16_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.08.009"},{"key":"e_1_2_16_111_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590\u2010020\u201000834\u20109"},{"key":"e_1_2_16_112_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590\u2010020\u20100725\u20102"},{"key":"e_1_2_16_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.04.026"},{"key":"e_1_2_16_114_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1679"},{"key":"e_1_2_16_115_1","doi-asserted-by":"publisher","DOI":"10.7555\/JBR.26.20120115"},{"key":"e_1_2_16_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.016"},{"key":"e_1_2_16_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115210"},{"key":"e_1_2_16_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010019\u20101897\u20105"},{"key":"e_1_2_16_119_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010018\u201006654\u20108"},{"key":"e_1_2_16_120_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.84"},{"key":"e_1_2_16_121_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010022\u201031250\u20102"},{"key":"e_1_2_16_122_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201004\u2010843714"},{"key":"e_1_2_16_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.003"},{"key":"e_1_2_16_124_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133977"},{"key":"e_1_2_16_125_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.185"},{"key":"e_1_2_16_126_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20062512"},{"key":"e_1_2_16_127_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00162"},{"key":"e_1_2_16_128_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.shk.0000245014.96419.3a"},{"key":"e_1_2_16_129_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.cd\u201019\u20101008"},{"key":"e_1_2_16_130_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010019\u20100728\u20103"},{"key":"e_1_2_16_131_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.242974"},{"key":"e_1_2_16_132_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010021\u201023331\u20105"},{"key":"e_1_2_16_133_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.cd\u201019\u20100980"},{"key":"e_1_2_16_134_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201005\u2010282780"},{"key":"e_1_2_16_135_1","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.18001"},{"key":"e_1_2_16_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2020.12.002"},{"key":"e_1_2_16_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.05.013"},{"key":"e_1_2_16_138_1","doi-asserted-by":"publisher","unstructured":"S.Gholamin HMNatri YZhao et\u00a0al. \u201cOvercoming Myeloid\u2010Driven Resistance to CAR T Therapy by Targeting SPP1 \u201dbioRxiv [Preprint] (2025):646202 https:\/\/doi.org\/10.1101\/2025.04.01.646202.","DOI":"10.1101\/2025.04.01.646202"},{"key":"e_1_2_16_139_1","unstructured":"University of Pennsylvania. \u201cPhase 1 Open\u2010Label Study Evaluating the Safety and Feasibility of CART\u2010EGFR\u2010IL13Ra2 Cells in Patients With EGFR\u2010Amplified Recurrent Glioblastoma \u201d (2025) https:\/\/clinicaltrials.gov\/study\/NCT05168423."},{"key":"e_1_2_16_140_1","unstructured":"M. V.Maus \u201cINCIPIENT: Intraventricular CARv3\u2010TEAM\u2010E T Cells for PatIENTs With GBM \u201d (2025) https:\/\/clinicaltrials.gov\/study\/NCT05660369."},{"key":"e_1_2_16_141_1","unstructured":"Stanford University. \u201cPhase I Clinical Trial of Locoregionally (LR) Delivered Autologous B7\u2010H3 Chimeric Antigen Receptor T Cells (B7\u2010H3CART) in Adults With Recurrent Glioblastoma Multiforme (GBM) \u201d (2025) https:\/\/clinicaltrials.gov\/study\/NCT05474378."},{"key":"e_1_2_16_142_1","unstructured":"F.Locatelli \u201cPhase I\/II Study of Anti\u2010GD2 Chimeric Antigen Receptor\u2010Expressing T Cells in Pediatric Patients Affected by High Risk and\/or Relapsed\/Refractory Neuroblastoma or Other GD2\u2010Positive Solid Tumors \u201d (2025) https:\/\/clinicaltrials.gov\/study\/NCT03373097."},{"key":"e_1_2_16_143_1","unstructured":"J.Mahdi \u201cPhase I Study of Autologous T Lymphocytes Expressing GD2\u2010Specific Chimeric Antigen and Constitutively Active IL\u20107 Receptors for the Treatment of Patients With GD2\u2010Expressing Brain Tumors (GAIL\u2010B) \u201d (2026) https:\/\/clinicaltrials.gov\/study\/NCT04099797."},{"key":"e_1_2_16_144_1","unstructured":"Shanghai PerHum Therapeutics Co. Ltd. A Phase I Trial to Assess Safety. \u201cTolerability and Anti\u2010Tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) (CCT303\u2010406) in Patients With Relapsed or Refractory HER2 Positive Solid Tumors \u201d (2024) https:\/\/clinicaltrials.gov\/study\/NCT04511871."},{"key":"e_1_2_16_145_1","unstructured":"Shanghai Cell Therapy Group Co. Ltd.An Exploratory Study on the Treatment of Advanced Solid Tumors by Secretory PD1 Nanoantibody Targeting Mesothelin Fast CAR T Cells (2024) https:\/\/clinicaltrials.gov\/study\/NCT06249256."},{"key":"e_1_2_16_146_1","volume-title":"Heterozygous HLA\u2010A*02 Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors that Express MSLN and Have Lost HLA\u2010A*02 Expression","author":"A2 Biotherapeutics Inc","year":"2026"},{"key":"e_1_2_16_147_1","unstructured":"B.Essen \u201cDual\u2010Target Chimeric Antigen Receptor (CAR) T\u2010Cell Therapy Directed Against Mesothelin and Claudin 18.2 in Patients With Advanced or Metastatic Pancreatic Cancer \u201d (2025) https:\/\/clinicaltrials.gov\/study\/NCT07066995."},{"key":"e_1_2_16_148_1","unstructured":"W.Zhang \u201cA Clinical Study to Evaluate the Safety and Efficacy of Anti\u2010CEA CAR\u2010T Cells in the Treatment of Postoperative Minimal Residual Lesions in Colorectal Cancer Patients With Liver Metastases \u201d (2022) https:\/\/clinicaltrials.gov\/study\/NCT05240950."},{"key":"e_1_2_16_149_1","unstructured":"Innovative Cellular Therapeutics Inc. \u201cA Phase 1 Multicenter Study Evaluating the Safety and Tolerability of GCC19CART for Subjects With Relapsed or Refractory Metastatic Colorectal Cancer \u201d (2023) https:\/\/clinicaltrials.gov\/study\/NCT05319314."},{"key":"e_1_2_16_150_1","unstructured":"CARsgen Therapeutics Co. Ltd.Open\u2010Label Multicenter Phase 1b\/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti\u2010Claudin 18.2 Chimeric Antigen Receptor T\u2010Cell Therapy in Subjects with Advanced Gastric Pancreatic or Other Specified Digestive System Cancers (2025) https:\/\/clinicaltrials.gov\/study\/NCT04404595."},{"key":"e_1_2_16_151_1","unstructured":"CARsgen Therapeutics Co. Ltd.An Open Multicenter Phase Ib\/II Study to Evaluate the Efficacy Safety and Pharmacokinetics of CT041 Autologous CAR T\u2010Cell Injection in Patients with Advanced Gastric\/Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer (2025) https:\/\/clinicaltrials.gov\/study\/NCT04581473."},{"key":"e_1_2_16_152_1","unstructured":"OriCell Therapeutics Co. Ltd.A Phase Ib\/II Open\u2010Label Multi\u2010Center Study to Investigate the Safety PK and Efficacy of Ori\u2010C101 in Advanced Hepatocellular Carcinoma (HCC) Patients (BEACON) (2024) https:\/\/clinicaltrials.gov\/study\/NCT05652920."},{"key":"e_1_2_16_153_1","unstructured":"T.Liang \u201cA Clinical Study to Evaluate Safety and Efficacy of C\u2010CAR031 Armored CAR\u2010T Cell Injection in Treatment of Advanced Hepatocellular Carcinoma \u201d (2026) https:\/\/clinicaltrials.gov\/study\/NCT05155189."},{"key":"e_1_2_16_154_1","unstructured":"A.AstraZeneca \u201cPhase I\/II Open\u2010Label Study to Evaluate the Safety Cellular Kinetics and Efficacy of AZD5851 a Chimeric Antigen Receptor T\u2010Cell (CAR\u2010T) Therapy Directed Against GPC3 in Adult Participants With Advanced\/Recurrent Hepatocellular Carcinoma: ATHENA \u201d (2026) https:\/\/clinicaltrials.gov\/study\/NCT06084884."},{"key":"e_1_2_16_155_1","unstructured":"T.Armaghnay \u201cInterleukin\u201015 Armored Glypican\u20103\u2010Specific Chimeric Antigen Receptor Expressing Autologous T Cells as Immunotherapy for Patients With SOLID TUMORS (CATCH) \u201d (2026) https:\/\/clinicaltrials.gov\/study\/NCT05103631."},{"key":"e_1_2_16_156_1","unstructured":"J.Xu \u201cA Phase I Clinical Trial for Evaluating the Safety Tolerance and Efficacy of GPC3\u2010Targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma \u201d (2024) https:\/\/clinicaltrials.gov\/study\/NCT05352542."},{"key":"e_1_2_16_157_1","unstructured":"Second Affiliated Hospital of Guangzhou Medical University. \u201cGPC3\/Mesothelin Targeted CAR\u2010\u03b3\u03b4T for Immunotherapy of Solid Cancer: Phase I Clinical Trial \u201d (2024) https:\/\/clinicaltrials.gov\/study\/NCT06196294."},{"key":"e_1_2_16_158_1","unstructured":"Allogene Therapeutics. \u201cA Phase 1A\/1B Multicenter Study Evaluating the Safety and Efficacy of ALLO\u2010316 With Cyclophosphamide\/Fludarabine Lymphodepletion Alone or Including ALLO\u2010647 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC) \u201d (2025) https:\/\/clinicaltrials.gov\/study\/NCT04696731."},{"key":"e_1_2_16_159_1","unstructured":"City of Hope Medical Center. \u201cA Phase I Study to Evaluate PSCA\u2010Targeting Chimeric Antigen Receptor (CAR)\u2010T Cells for Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer \u201d (2025) https:\/\/clinicaltrials.gov\/study\/NCT03873805."},{"key":"e_1_2_16_160_1","unstructured":"W.Fang \u201cClinical Trial for the Safety and Efficacy of Non\u2010Viral PD1 Integrated Anti\u2010PSMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Castrate\u2010Resistant Prostate Cancer \u201d (2023) https:\/\/clinicaltrials.gov\/study\/NCT04768608."},{"key":"e_1_2_16_161_1","unstructured":"L.\u2010J.Chang Intervention of Advanced or Metastatic Urothelial Bladder Cancer by 4SCAR\u2010T Cell Therapies (2025) https:\/\/clinicaltrials.gov\/study\/NCT03185468."},{"key":"e_1_2_16_162_1","unstructured":"Y.Zhang \u201cSafety Tolerability and Efficacy of Enhanced IL\u201013R\u03b12 Targeted Chimeric Antigen Receptor T Cell Immunotherapy Against Recurrent\/Refractory Grade 4 Glioma \u201d (2026) https:\/\/clinicaltrials.gov\/study\/NCT06355908."},{"key":"e_1_2_16_163_1","unstructured":"City of Hope Medical Center. \u201cA Phase 1 Study to Evaluate IL13R\u03b12\u2010Targeted Chimeric Antigen Receptor (CAR) T Cells Combined With Checkpoint Inhibition for Patients With Resectable Recurrent Glioblastoma \u201d (2025) https:\/\/clinicaltrials.gov\/study\/NCT04003649."},{"key":"e_1_2_16_164_1","unstructured":"Fudan University. \u201cA Phase I Clinical Trial of NKG2D\u2010Based CAR T\u2010Cells Injection for Subjects With Relapsed\/Refractory NKG2DL+ Solid Tumors \u201d (2021) https:\/\/clinicaltrials.gov\/study\/NCT05131763."},{"key":"e_1_2_16_165_1","unstructured":"Jiujiang University Affiliated Hospital. \u201cA Phase I Clinical Trial of NKG2D\u2010Based CAR T\u2010Cells Injection for Subjects With Relapsed\/Refractory NKG2DL+ Solid Tumors \u201d (2020) https:\/\/clinicaltrials.gov\/study\/NCT04270461."},{"key":"e_1_2_16_166_1","unstructured":"Second Affiliated Hospital of Guangzhou Medical University.CAR\u2010T Targeting GPC3 Mesothelin Claudin18.2 GUCY2C B7\u2010H3 PSCA PSMA MUC1 TGF\u03b2 HER2 Lewis\u2010Y AXL or EGFR for Immunotherapy of Lung Cancer: Phase I Clinical Trial (2024) https:\/\/clinicaltrials.gov\/study\/NCT03198052."},{"key":"e_1_2_16_167_1","unstructured":"March Biosciences Inc. \u201cA Phase 2 Open\u2010Label Multicenter Study of MB\u2010105 in Patients With CD5 Positive (CD5+) Relapsed\/Refractory T\u2010Cell Lymphoma (r\/r TCL) \u201d (2025) https:\/\/clinicaltrials.gov\/study\/NCT06534060."},{"key":"e_1_2_16_168_1","unstructured":"Kite A Gilead Company. \u201cA Phase 1\/2 Multicenter Study Evaluating the Safety and Efficacy of KTE\u2010C19 in Adults With Refractory Aggressive Non\u2010Hodgkin Lymphoma \u201d (2024) https:\/\/clinicaltrials.gov\/study\/NCT02348216."},{"key":"e_1_2_16_169_1","unstructured":"Juno Therapeutics a Subsidiary of Celgene.A Phase 1 Multicenter Open\u2010Label Study of JCAR017 CD19\u2010Targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed and Refractory (R\/R) B\u2010Cell Non\u2010Hodgkin Lymphoma (NHL) (2024) https:\/\/clinicaltrials.gov\/study\/NCT02631044."},{"key":"e_1_2_16_170_1","unstructured":"UNC Lineberger Comprehensive Cancer Center. \u201cPhase Ib\/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed\/Refractory CD30+ Hodgkin\u2019s Lymphoma and CD30+ Non\u2010hodgkin\u2019s Lymphoma \u201d (2026) https:\/\/clinicaltrials.gov\/study\/NCT02690545."},{"key":"e_1_2_16_171_1","unstructured":"C.Ramos \u201cPhase I Study of Relapsed CD30 Expressing Lymphoma Treated With CD30 CAR T Cells (RELY\u201030) \u201d (2025) https:\/\/clinicaltrials.gov\/study\/NCT02917083."},{"key":"e_1_2_16_172_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201004\u2010711903"},{"key":"e_1_2_16_173_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.002"},{"key":"e_1_2_16_174_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201002893\u2010z"},{"key":"e_1_2_16_175_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1610497"},{"key":"e_1_2_16_176_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2314390"},{"key":"e_1_2_16_177_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201018\u20100432"},{"key":"e_1_2_16_178_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201003037\u2010z"},{"key":"e_1_2_16_179_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.4017"},{"key":"e_1_2_16_180_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.3582"},{"key":"e_1_2_16_181_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.03.010"},{"key":"e_1_2_16_182_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.272"},{"key":"e_1_2_16_183_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201019\u20103259"},{"key":"e_1_2_16_184_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4019"},{"key":"e_1_2_16_185_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010024\u201008261\u20108"},{"key":"e_1_2_16_186_1","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202508754"},{"key":"e_1_2_16_187_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.cd\u201024\u20100102"},{"key":"e_1_2_16_188_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201002979\u20108"},{"key":"e_1_2_16_189_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441"},{"key":"e_1_2_16_190_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108734"},{"key":"e_1_2_16_191_1","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac185"},{"key":"e_1_2_16_192_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.adv7378"},{"key":"e_1_2_16_193_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010023\u201002169\u2010z"},{"key":"e_1_2_16_194_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010200204"},{"key":"e_1_2_16_195_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15_suppl.8503"},{"key":"e_1_2_16_196_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000967720.61024.68"},{"key":"e_1_2_16_197_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP\u201025\u201000542"},{"key":"e_1_2_16_198_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1610544113"},{"key":"e_1_2_16_199_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419\u2010025\u201008405\u20102"},{"key":"e_1_2_16_200_1","unstructured":"D.Steffin \u201cGlypican 3\u2010Specific Chimeric Antigen Receptor Expressed in Autologous T Cells as Immunotherapy for Patients With Pediatric Solid Tumors \u201d (2025) https:\/\/clinicaltrials.gov\/study\/NCT02932956."},{"key":"e_1_2_16_201_1","unstructured":"T.Armaghnay \u201cGlypican 3\u2010Specific Chimeric Antigen Receptor Expressing T Cells as Immunotherapy for Patients With Hepatocellular Carcinoma \u201d (2025) https:\/\/clinicaltrials.gov\/study\/NCT02905188."},{"key":"e_1_2_16_202_1","unstructured":"D.Steffin Interleukin\u201015 Armored Glypican\u20103\u2010Specific Chimeric Antigen Receptor Expressing Autologous T Cells as Immunotherapy for Children with Solid Tumors (2026) https:\/\/clinicaltrials.gov\/study\/NCT04377932."},{"key":"e_1_2_16_203_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326\u20106066.cir\u201019\u20100293"},{"key":"e_1_2_16_204_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010025\u201009212\u20107"},{"key":"e_1_2_16_205_1","unstructured":"B.Omer \u201cPhase I Study of Autologous T Lymphocytes Expressing GD2\u2010Specific Chimeric Antigen and Constitutively Active IL\u20107 Receptors for the Treatment of Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Solid Cancers(GAIL\u2010N) \u201d (2025) https:\/\/clinicaltrials.gov\/study\/NCT03635632."},{"key":"e_1_2_16_206_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4086"},{"key":"e_1_2_16_207_1","unstructured":"The Sixth Affiliated Hospital of Wenzhou Medical University. \u201cIntegrin \u03927 BCMA CS1 CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR\u2010T Cells \u201d (2020) https:\/\/clinicaltrials.gov\/study\/NCT03778346."},{"key":"e_1_2_16_208_1","unstructured":"W.Qian \u201cInterleukin\u20107 and Chemokine (C\u2010C Motif) \u2010Ligand 19\u2010Expressing CD19\u2010CAR\u2010T for Refractory\/Relapsed B Cell Lymphoma \u201d (2019) https:\/\/clinicaltrials.gov\/study\/NCT03929107."},{"key":"e_1_2_16_209_1","unstructured":"Second Affiliated Hospital School of Medicine Zhejiang University.Clinical Follow\u2010up Study of CD19 CAR\u2010T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma (2025) https:\/\/clinicaltrials.gov\/study\/NCT04833504."},{"key":"e_1_2_16_210_1","unstructured":"Ningbo No. 1 Hospital. \u201cPhase Ib Clinical Study of CD19 CAR\u2010T Expressing IL\u20107 and CCL19 Combined With Tislelizumab in the Treatment of Relapsed\/Refractory Diffuse Large B\u2010Cell Lymphoma \u201d (2022) https:\/\/clinicaltrials.gov\/study\/NCT05659628."},{"key":"e_1_2_16_211_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010021\u201001128\u20109"},{"key":"e_1_2_16_212_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.11.007"},{"key":"e_1_2_16_213_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010020\u20100874\u20101"},{"key":"e_1_2_16_214_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157175"},{"key":"e_1_2_16_215_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201014\u20102085"},{"key":"e_1_2_16_216_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010023\u201040115\u20101"},{"key":"e_1_2_16_217_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.10.011"},{"key":"e_1_2_16_218_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci166028"},{"key":"e_1_2_16_219_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2408771"},{"key":"e_1_2_16_220_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.11.063"},{"key":"e_1_2_16_221_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.09.002"},{"key":"e_1_2_16_222_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022293"},{"key":"e_1_2_16_223_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41587\u2010019\u20100398\u20102"},{"key":"e_1_2_16_224_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967\u2010019\u201002206\u2010w"},{"key":"e_1_2_16_225_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4195"},{"key":"e_1_2_16_226_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.06.002"},{"key":"e_1_2_16_227_1","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2011.81"},{"key":"e_1_2_16_228_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24"},{"key":"e_1_2_16_229_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262\u2010017\u20102034\u20107"},{"key":"e_1_2_16_230_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.25.14827"},{"key":"e_1_2_16_231_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1407222"},{"key":"e_1_2_16_232_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136012"},{"key":"e_1_2_16_233_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102023\u2010008566"},{"key":"e_1_2_16_234_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943\u2010024\u201001952\u2010w"},{"key":"e_1_2_16_235_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010018\u20100036\u20104"},{"key":"e_1_2_16_236_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201006\u2010793141"},{"key":"e_1_2_16_237_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010018\u20100041\u20107"},{"key":"e_1_2_16_238_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.cd\u201017\u20101319"},{"key":"e_1_2_16_239_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.cd\u201017\u20100698"},{"key":"e_1_2_16_240_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102024\u2010010083"},{"key":"e_1_2_16_241_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010022\u201001800\u20108"},{"key":"e_1_2_16_242_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17662"},{"key":"e_1_2_16_243_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008893"},{"key":"e_1_2_16_244_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018894618"},{"key":"e_1_2_16_245_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.012"},{"key":"e_1_2_16_246_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.am2025\u2010ct186"},{"key":"e_1_2_16_247_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.06.014"},{"key":"e_1_2_16_248_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.cd\u201017\u20100263"},{"key":"e_1_2_16_249_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010024\u201053220\u20106"},{"key":"e_1_2_16_250_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907"},{"key":"e_1_2_16_251_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010020\u201020671\u20106"},{"key":"e_1_2_16_252_1","doi-asserted-by":"publisher","DOI":"10.1021\/acssynbio.1c00236"},{"key":"e_1_2_16_253_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1106152"},{"key":"e_1_2_16_254_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102004\u201011\u20104564"},{"key":"e_1_2_16_255_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201018\u20103069"},{"key":"e_1_2_16_256_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2210859"},{"key":"e_1_2_16_257_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1995.6.6\u2010813"},{"key":"e_1_2_16_258_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmmed.2022.1026474"},{"key":"e_1_2_16_259_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024104"},{"key":"e_1_2_16_260_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010024\u201001082\u2010y"},{"key":"e_1_2_16_261_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.01.012"},{"key":"e_1_2_16_262_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100227"},{"key":"e_1_2_16_263_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102021\u2010002755"},{"key":"e_1_2_16_264_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70209","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.70209","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:36:23Z","timestamp":1788276983000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.70209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":263,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/hon.70209"],"URL":"https:\/\/doi.org\/10.1002\/hon.70209","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"2026-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70209"}}